title: Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.
abstract: Vicrostatin (VCN) is a chimeric recombinant disintegrin generated in Origami B (DE3) Escherichia coli as a genetic fusion between the C-terminal tail of a viperid disintegrin echistatin and crotalid disintegrin contortrostatin (CN). The therapeutic modulation of multiple integrin pathways via soluble disintegrins was previously shown by us and others to elicit potent anti-angiogenic and anti-metastatic effects in several animal cancer models. Despite these favorable attributes, these polypeptides are notoriously difficult to produce recombinantly in significant quantity due to their structure which requires the correct pairing of multiple disulfide bonds for biological activity. In this report, we show that VCN can be reliably produced in large amounts (yields in excess of 200 mg of active purified disintegrin per liter of bacterial culture) in Origami B (DE3), an E. coli expression strain engineered to support the folding of disulfide-rich heterologous proteins directly in its oxidative cytoplasmic compartment. VCN retains the integrin binding specificity of both parental molecules it was derived from, but with a different binding affinity profile. While competing for the same integrin receptors that are preferentially upregulated in the tumor microenvironment, VCN exerts a potent inhibitory effect on endothelial cell (EC) migration and tube formation in a dose-dependent manner, by forcing these cells to undergo significant actin cytoskeleton reorganization when exposed to this agent in vitro. Moreover, VCN has a direct effect on breast cancer cells inhibiting their in vitro motility. In an effort to address our main goal of developing a clinically relevant delivery method for recombinant disintegrins, VCN was efficiently packaged in liposomes (LVCN) and evaluated in vivo in an animal breast cancer model. Our data demonstrate that LVCN is well tolerated, its intravenous administration inducing a significant delay in tumor growth and an increase in animal survival, results that can be partially explained by potent tumor apoptotic effects.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Southern California, Keck School of Medicine, 1303 N Mission Road, CRL-106, Los Angeles, CA 90033, USA.
authors.forename: Radu
authors.initials: R
authors.lastname: Minea
authors.forename: Corey
authors.initials: C
authors.lastname: Helchowski
authors.forename: Barbara
authors.initials: B
authors.lastname: Rubino
authors.forename: Kyle
authors.initials: K
authors.lastname: Brodmann
authors.forename: Stephen
authors.initials: S
authors.lastname: Swenson
authors.forename: Francis
authors.initials: F
authors.lastname: Markland
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism; D045744:Cell Line, Tumor / Q000187:drug effects; D002470:Cell Survival; D003362:Cost-Benefit Analysis; D004195:Disease Models, Animal; D019483:Disintegrins / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D005260:Female; D015964:Gene Expression Regulation, Bacterial; D050939:Gene Fusion; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology*; D008081:Liposomes / Q000378:metabolism; D051379:Mice; D008969:Molecular Sequence Data; D011485:Protein Binding; D016415:Sequence Alignment
chemical_list: D000970:Antineoplastic Agents; D019483:Disintegrins; D000922:Immunotoxins; D008081:Liposomes; C551792:vicrostatin